Tumor acidity, chemoresistance and proton pump inhibitors. - Test2 - elhamkhani - TriplyDB

Tumor acidity, chemoresistance and proton pump inhibitors.

Tumor acidity, chemoresistance and proton pump inhibitors.

http://www.wikidata.org/entity/Q36429624

about

Nitric oxide and pH modulation in gynaecological cancer In vivo Magnetic Resonance Metabolic and Morphofunctional Fingerprints in Experimental Models of Human Ovarian Cancer Targeting Notch to overcome radiation resistance Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles PLGA nanoparticle encapsulation reduces toxicity while retaining the therapeutic efficacy of EtNBS-PDT in vitro ROS homeostasis and metabolism: a critical liaison for cancer therapy TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells The Intercellular Metabolic Interplay between Tumor and Immune Cells Extracellular glucose increases the coupling capacity of the yeast V H+-ATPase and the resistance of its H+ transport activity to nitrate inhibition Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin Investigating Effects of Acidic pH on Proliferation, Invasion and Drug-Induced Apoptosis in Lymphoblastic Leukemia.Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery.Hypoxia-induced mobilization of NHE6 to the plasma membrane triggers endosome hyperacidification and chemoresistance.Bicarbonate and dichloroacetate: evaluating pH altering therapies in a mouse model for metastatic breast cancer High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors.Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs Tumor acidity as evolutionary spite.Utilizing hydrogen sulfide as a novel anti-cancer agent by targeting cancer glycolysis and pH imbalance.Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells Normal and polar-organic-phase high-performance liquid chromatographic enantioresolution of omeprazole, rabeprazole, lansoprazole and pantoprazole using monochloro-methylated cellulose-based chiral stationary phase and determination of dexrabeprazol Enantiomeric separation of proton pump inhibitors on new generation chiral columns using LC and supercritical fluid chromatography.Intratumoral decorin gene delivery by AAV vector inhibits brain glioblastomas and prolongs survival of animals by inducing cell differentiation.Synthesis and characterization of lipid-polymer hybrid nanoparticles with pH-triggered poly(ethylene glycol) shedding.Vacuolar ATPase 'a2' isoform exhibits distinct cell surface accumulation and modulates matrix metalloproteinase activity in ovarian cancer Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer Proton pump inhibitors for the treatment of cancer in companion animals.Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk.Autophagy is a protective mechanism for human melanoma cells under acidic stress.Evidence-based support for the use of proton pump inhibitors in cancer therapy Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma.Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.Visualizing and manipulating focal adhesion kinase regulation in live cells.Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.Lysosomes in iron metabolism, ageing and apoptosis.Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo.Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed

P2860

Q26741063-99E77628-B369-47EE-9347-FE58CFBDA1B0 Q26742109-7A1F5171-6C37-4100-B55D-118E1E480E48 Q26771701-0DDE12CA-D87C-4C1D-8288-138308256FB9 Q27026080-7D5F92D1-713C-4A11-9D0B-46AE4733C8EF Q27348681-C041E549-EE7E-449D-89ED-B46821352391 Q28080316-3432DF42-826A-4764-A8E6-C9BFF6E4DB4F Q28119089-97FC2CFB-B6FE-467F-8A43-032B42AABBE4 Q28391079-C7065D58-2C85-4E91-B9A9-6D1938784359 Q28485328-B7F11A68-C6B6-43C7-91F3-323D744934F6 Q28535295-3138ADCC-57FA-4C58-A402-24965DCD7E38 Q28539631-475A3B17-DE4A-4C8F-A964-AD8DD0DC2128 Q30363892-024274C3-3C9B-4403-B6F7-42165C75C4BD Q31116734-9F422494-EC6D-4CD1-B4B8-F30B6C611843 Q33572677-5EE81F29-AA98-4A99-9D3C-158D28CB0473 Q33794267-413E0EBE-241C-42D5-9D39-1477DDC813C0 Q33827896-1FC7B9B6-5A81-4489-B613-A31E44723471 Q33929658-56646F0F-26A8-4E2F-8932-71EF972749FF Q34091419-3DDC7DA0-55C5-4B5A-8058-844D22A97482 Q34304788-0782F39E-88E3-4A93-86E1-C97F5A21645B Q34390027-F33E76DA-71ED-4D15-8B8E-C9695C4EE099 Q34559610-9522C7EB-919C-4070-95F1-619D2CA6981A Q34561771-C222420E-5D3F-424E-B23C-414967EB264A Q34686617-DC2A01C9-20A1-429C-A75D-98CB9BB064F4 Q34822438-E0104865-6015-4515-BB86-150AE8A9142F Q35119851-5C8E99FA-9ACD-41D6-B39F-54185AAD19C0 Q35193987-BCA036CC-8198-4432-9508-191E15FE8B5C Q35551874-9F092D4D-7DF3-4C3C-A967-692AFBB7C3D0 Q35987082-8D894866-DA49-42BF-A252-C33FA1F84DAB Q36027301-07E54DB2-6DED-48B6-9514-7E00CCF5AA19 Q36201760-A8A3481F-064E-478F-BCDF-A7A49AD42B28 Q36216450-23FB8FA0-A713-4646-A6A0-8698BE293722 Q36310900-55D31D71-66F7-4076-BA7D-2008597F7E38 Q36422761-F4E8D816-4E12-44B6-81A0-CE14995B335C Q36544294-78AA23E8-9201-44AB-BB10-B2B6DBF04223 Q36680180-381F2EC5-4A20-4CB4-AF54-1C41E584558F Q36724913-F26C2008-C980-4A19-B4CE-9820B4FD2D3B Q36845140-FCA1D557-F0B0-4CBA-A1FB-A8DFB7E3A379 Q37079830-BF18B731-2EFA-4642-8A7E-BB18085D6BC8 Q37146401-EC974D1A-25E3-4547-BD71-9962388294B1 Q37273398-668DB53F-8D58-4646-8918-3A4A31484846

P2860

Tumor acidity, chemoresistance and proton pump inhibitors.

http://www.wikidata.org/entity/Q36429624

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Tumor acidity, chemoresistance and proton pump inhibitors.

@ast

Tumor acidity, chemoresistance and proton pump inhibitors.

@en

type

label

Tumor acidity, chemoresistance and proton pump inhibitors.

@ast

Tumor acidity, chemoresistance and proton pump inhibitors.

@en

prefLabel

Tumor acidity, chemoresistance and proton pump inhibitors.

@ast

Tumor acidity, chemoresistance and proton pump inhibitors.

@en

P1433

Q36429624-326BC2F9-4B37-42B0-B755-9565763DA629

P1476

Q36429624-956F2AF5-CA11-4252-B043-A7E793C4E4A9

P2093

Q36429624-4CEF3C3E-C5B8-4964-9776-5BAEDDD704EC

Q36429624-C14C7E94-26A2-491C-9820-1F979394EABE

P2860

Q36429624-0A61D641-DCF6-4422-8944-A911E14677D8

Q36429624-0B7341F8-5B3A-44BD-8159-EB6F49DE0A83

Q36429624-0E8236A8-F944-42CE-8AD0-49822E1D9CEA

Q36429624-18E8F24A-C03D-4320-8AF7-70EE387478FA

Q36429624-1B7D5B59-D6B3-4D04-B8A4-B44F141A6B82

Q36429624-1EAFC1B5-7A44-4855-83E4-388AA5281EB5

Q36429624-21085C01-57D3-49B6-A372-EA77E4F0C99E

Q36429624-2C9C626D-E482-4725-9DDD-2EC2F585EEF5

Q36429624-2F3ACD6D-1008-49E6-AB4D-0BB9577616D9

Q36429624-303A7C9C-9AF3-4117-91EB-D54439E4C647

P304

Q36429624-46B55607-39D1-4CE6-9F54-E0AB588EA43B

P31

Q36429624-8D4F4E05-2262-490C-8E38-CF32004F6FFD

P356

Q36429624-1C8C4BF8-17D0-4920-8D56-786D3841B466

P407

Q36429624-D853759D-34DF-4478-AEB9-A2CA4BAB6A72

P433

Q36429624-26004CED-2DAC-48D2-B8D1-1A8B00575400

P478

Q36429624-56F34C8E-357D-40B8-9221-F8454ACC1C12

P50

Q36429624-C7961B38-1305-4778-B98C-21656F743FA6

Q36429624-CDBAC2DF-C676-4C4C-9271-2F6BC5D4EA27

P577

Q36429624-336AC83A-C82D-46F7-A094-BEF0B9C924D8

P698

Q36429624-623C1DE4-0810-4CB0-933A-E89A33B50849

P356

14796694.1.6.779

P1433

Future Oncology

P1476

Tumor acidity, chemoresistance and proton pump inhibitors

@en

P2093

Angelo De Milito

http://www.w3.org/2001/XMLSchema#string

Stefano Fais

http://www.w3.org/2001/XMLSchema#string

P2860

On the Origin of Cancer Cells

Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro

Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy

Why do cancers have high aerobic glycolysis?

Acute metabolic alkalosis enhances response of C3H mouse mammary tumors to the weak base mitoxantrone

Murine monoclonal antibody recognizing a 90-kDa cell-surface determinant selectively lost by multi-drug-resistant variants of CEM cells.

Enhancement of chemotherapy by manipulation of tumour pH.

Studies of human tumors by MRS: a review.

Microarray data simulator for improved selection of differentially expressed genes.

Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.

P304

779-786

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14796694.1.6.779

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Angelo De Milito

P577

2005-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16556057

http://www.w3.org/2001/XMLSchema#string